Discovering genetic biomarkers for targeted cancer therapeutics with eXplainable Artificial Intelligence

References

[1] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(1):17-48.

[2] Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC,, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15(11):668-679.

[3] Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, et al. Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020;31(9):1240-1250.

[4] Garsed DW, Pandey A, Fereday S, Kennedy CJ, Takahashi K, Alsop K, et al. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nature genetics. 2022;54(12):1853-1864.

[5] Shmatko A, Ghaffari Laleh N, Gerstung M, Kather JN. Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. Nat Cancer. 2022;3(9):1026-1038.

[6] Kundu S. AI in medicine must be explainable. Nature Medicine. 2021;27(8):1328.

[7] Dibra D, Mitra A, Newman M, Xia X, Cutrera JJ, Gagea M, et al. Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo. Clin Cancer Res. 2016;22(15):3876-3883.

[8] Aghayev T, Mazitova AM, Fang JR, Peshkova IO, Rausch M, Hung M, et al. IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma. Cancer discovery. 2022;12(8):1960-1983.

[9] Babic B, Gerke S, Evgeniou T, Cohen IG. Beware explanations from AI in health care. Science. 2021;373;284-286.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd on behalf of Sun Yat-sen University Cancer Center.